Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Taka-aki Matsuoka, Kaoru Yamamoto, Yoshifumi Maeno, Yuka Shiraiwa, Yoko Yoshida, Naoto Katakami, Hiroaki Iijima, Hideyuki Katsumata, Kenji Arakawa, Toshio Hashimoto & Iichiro Shimomura. (2020) Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity 13, pages 4457-4468.
Read now
Read now
Satoko Kawarasaki, Honami Sawazaki, Hiroaki Iijima, Su-Ping Ng, Jungin Kwon, Shinsuke Mohri, Mari Iwase, Huei-Fen Jheng, Haruya Takahashi, Wataru Nomura, Kazuo Inoue, Teruo Kawada & Tsuyoshi Goto. (2020) Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism. Diabetes, Metabolic Syndrome and Obesity 13, pages 4353-4359.
Read now
Read now
André J Scheen. (2020) SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients. Diabetes, Metabolic Syndrome and Obesity 13, pages 2765-2779.
Read now
Read now
Yuya Seko, Taichiro Nishikawa, Atsushi Umemura, Kanji Yamaguchi, Michihisa Moriguchi, Kohichiroh Yasui, Mayumi Kimura, Hiroaki Iijima, Toshio Hashimoto, Yoshio Sumida, Takeshi Okanoue & Yoshito Itoh. (2018) Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. Diabetes, Metabolic Syndrome and Obesity 11, pages 835-843.
Read now
Read now
Articles from other publishers (11)
Satoko Kawarasaki, Honami Sawazaki, Hiroaki Iijima, Haruya Takahashi, Wataru Nomura, Kazuo Inoue, Teruo Kawada & Tsuyoshi Goto. (2023) Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression. European Journal of Pharmacology 947, pages 175682.
Crossref
Crossref
Jaime A Davidson, Norlela Sukor, Fen‐Lee Hew, Mafauzy Mohamed & Zanariah Hussein. (2022)
Safety of sodium–glucose c
otransporter
2 inhibitors in Asian type 2 diabetes populations
. Journal of Diabetes Investigation 14:2, pages 167-182.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Hirotaka Watada, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki & Tatsuki Teranishi. (2022) Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan. Advances in Therapy 39:4, pages 1642-1658.
Crossref
Crossref
Nobuya Inagaki, Masaomi Nangaku, Yasushi Sakata, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki & Koume Hamada. (2021) Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance. Advances in Therapy 39:1, pages 674-691.
Crossref
Crossref
L P Zhou, F Qiu, Z F Zhang, C M Wang, Y L Dong & J P Liu. (2020) SYNTHESIS, CRYSTAL STRUCTURE, ANTI-LUNG
CANCER ACTIVITY OF 2-(4-FLUOROPHENYL)-5-
(5-IODO-2-METHYLBENZYL)THIOPHENE. Journal of Structural Chemistry 61:7, pages 1111-1116.
Crossref
Crossref
Ikuro MatsubaAkira KanamoriMasahiro TakihataMasahiko TakaiHajime MaedaAkira KubotaKotaro IemitsuShinichi UmezawaMitsuo ObanaMizuki KaneshiroTakehiro KawataTetsuo TakumaHiroshi TakedaHideo MachimuraAtsuko MokuboTetsuya MotomiyaTaro AsakuraTaisuke KikuchiYoko MatsuzawaShogo ItoMasaaki MiyakawaYasuo TerauchiYasushi Tanaka. (2020) Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study. Diabetes Technology & Therapeutics 22:3, pages 228-234.
Crossref
Crossref
Kazuyuki Tobe, Hiroshi Maegawa, Hiromi Tabuchi, Ichiro Nakamura & Satoshi Uno. (2019) Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study. Journal of Diabetes Investigation 10:5, pages 1262-1271.
Crossref
Crossref
Jeffrey I. Mechanick, Stephanie Adams, Jaime A. Davidson, Icilma V. Fergus, Rodolfo J. Galindo, Kevin H. McKinney, Steven M. Petak, Archana R. Sadhu, Susan L. Samson, Rajesh Vedanthan & Guillermo E. Umpierrez. (2019) Transcultural Diabetes Care in The United States – A Position Statement by the American Association of Clinical Endocrinologists. Endocrine Practice 25:7, pages 729-765.
Crossref
Crossref
Xingyun Hou, Xu Wan & Bin Wu. (2019) Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China. Frontiers in Pharmacology 10.
Crossref
Crossref
Antonio Ceriello, Valeria De Nigris, Hiroaki Iijima, Takahiro Matsui & Maki Gouda. (2019) The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs 79:7, pages 733-750.
Crossref
Crossref
Yoko Koike, Shin-Ichiro Shirabe, Hajime Maeda, Ayako Yoshimoto, Keiko Arai, Atsushi Kumakura, Koichi Hirao & Yasuo Terauchi. (2019) Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 149, pages 140-146.
Crossref
Crossref